The Forty-Year-Old Equation That Guesses at Your Metabolic Future

So the deal with HOMA-IR — and it is worth slowing down here, because the whole thing is almost suspiciously elegant — is that you fast overnight (no breakfast, no coffee with anything in it, just water and patience), you give one tube of blood, and then a piece of arithmetic published in 1985 by Matthews and colleagues multiplies your fasting insulin by your fasting glucose and divides by 22.5 (classically, with insulin in µU/mL and glucose in mmol/L) — and out comes a single number that claims to estimate how resistant your body is to its own insulin, which is to say, one of the deepest questions in metabolic health, answered from one fasting sample.

Which raises the obvious question: can one number from one tube really carry that much? The defensible answer: more than you might think, and less than the longevity internet assumes. HOMA-IR is a genuine, validated surrogate — and it is only a surrogate.

Born as a shortcut, validated as one

The 1985 paper in Diabetologia introduced the homeostatic model assessment as a computer model of the glucose–insulin feedback loop, estimating insulin resistance and beta-cell function from basal concentrations. It was validated against the hyperinsulinaemic-euglycaemic clamp — the laborious reference method in which insulin is infused and glucose is clamped — and the correlation is real but moderate, not perfect. A 2002 study in Diabetes Care derived indices of insulin action, disposal, and secretion from fasting samples and clamps in normal glucose-tolerant children, testing exactly this correspondence. Indices such as QUICKI can outperform it. The shortcut works; it remains a shortcut.

What high values track with

Higher fasting insulin and HOMA-IR reflect greater insulin resistance — the central feature of metabolic syndrome — and insulin resistance precedes and predicts type 2 diabetes. In large cohorts and meta-analyses it is associated with increased risk of cardiovascular disease, all-cause and cardiovascular mortality, certain cancers, and, in older adults, frailty and its progression. The 2017 record in Bioscience Reports sits behind the fasting-insulin and HOMA-IR framing. These are associations from observational research — strong, replicated, and still associations. As risk-stratification tools in research, these markers have earned their place.

The fine print, from the source

The field's own conscience is a 2004 article in Diabetes Care titled, unforgettably, Use and abuse of HOMA modeling. The abuses it warned about are still with us: there is no universal cut-off, and thresholds vary by insulin assay, age, and ethnicity, which means a number that trips one lab's flag may sit inside another's normal. The associations themselves can buckle in surprising places — the PROSPER study, published in Diabetologia in 2014, found contrasting associations of insulin resistance with diabetes, cardiovascular disease, and all-cause mortality in the elderly, with weaker or null cardiovascular findings in the very old; other studies report null associations, for example between fasting insulin and breast cancer. The marker predicts powerfully in the middle of life and can go quiet at the extremes of age — a humbling detail for anyone planning to track one number forever.

For a reader, the practical meaning is compass, not verdict: a fasting draw read by the same assay over time can show a direction of travel in insulin sensitivity, especially alongside glucose and clinical context — but a single HOMA-IR, interpreted against someone else's cut-off, can mislead in both directions.

Which brings the story back to the little equation from 1985, still running quietly in laboratory software everywhere — two fasting numbers, one division by 22.5, and a guess about the future that is best treated as exactly that: an informed guess, from a model honest enough to have published its own warning label.

Educational, not medical advice.